Inhalable siRNA Nanoparticles for Enhanced Tumor-Targeting Treatment of KRAS-Mutant Non-Small-Cell Lung Cancer.

Kirsten rat sarcoma (KRAS) is the most commonly mutated oncogene in lung cancers. Gene therapy is emerging as a promising cancer treatment modality; however, the systemic administration of gene therapy has been limited by inefficient delivery to the lungs and systemic toxicity. Herein, we report a noninvasive aerosol inhalation nanoparticle (NP) system, termed "siKRAS@GCLPP NPs," to treat KRAS-mutant non-small-cell lung cancer (NSCLC). The self-assembled siKRAS@GCLPP NPs are capable of maintaining structural integrity during nebulization, with preferential distribution within the tumor-bearing lung. Inhalable siKRAS@GCLPP NPs show not only significant tumor-targeting capability but also enhanced antitumor activity in an orthotopic mouse model of human KRAS-mutant NSCLC. The nebulized delivery of siKRAS@GCLPP NPs demonstrates potent knockdown of mutated KRAS in tumor-bearing lungs without causing any observable adverse effects, exhibiting a better biosafety profile than the systemic delivery approach. The results present a promising inhaled gene therapy approach for the treatment of KRAS-mutant NSCLC and other respiratory diseases.

[1]  Zhongyu Li,et al.  Inhaled siRNA nanoparticles targeting IL11 inhibit lung fibrosis and improve pulmonary function post-bleomycin challenge , 2022, Science advances.

[2]  Liwu Fu,et al.  KRAS mutation: from undruggable to druggable in cancer , 2021, Signal Transduction and Targeted Therapy.

[3]  M. Berger,et al.  Diverse alterations associated with resistance to KRAS(G12C) inhibition , 2021, Nature.

[4]  James E. Dahlman,et al.  Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs , 2021, Nature Biomedical Engineering.

[5]  Kai Chen,et al.  A comparison of the monomeric [68Ga]NODAGA-NGR and dimeric [68Ga]NOTA-(NGR)2 as aminopeptidase N ligand for positron emission tomography imaging in tumor-bearing mice. , 2021, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[6]  C. Bieberich,et al.  Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models , 2021, Science Translational Medicine.

[7]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[8]  Junjie Zhu,et al.  Nanoparticle‐Mediated Delivery of Inhaled Immunotherapeutics for Treating Lung Metastasis , 2021, Advanced materials.

[9]  D. Hong,et al.  Therapeutics Targeting Mutant KRAS. , 2020, Annual review of medicine.

[10]  M. Oudkerk,et al.  Lung cancer LDCT screening and mortality reduction — evidence, pitfalls and future perspectives , 2020, Nature Reviews Clinical Oncology.

[11]  S. Novello,et al.  KRAS inhibition in non-small cell lung cancer: Past failures, new findings and upcoming challenges. , 2020, European journal of cancer.

[12]  H. Chan,et al.  Inhalation delivery technology for genome-editing of respiratory diseases , 2020, Advanced Drug Delivery Reviews.

[13]  Zhongyu Li,et al.  Biodegradable nanoparticles decorated with different carbohydrates for efficient macrophage-targeted gene therapy. , 2020, Journal of Controlled Release.

[14]  D. Chellappan,et al.  Patented therapeutic drug delivery strategies for targeting pulmonary diseases , 2020, Expert opinion on therapeutic patents.

[15]  A. Drilon,et al.  KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures. , 2020, Cancer treatment reviews.

[16]  Davide Risso,et al.  Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition , 2020, Nature.

[17]  T. Minko,et al.  Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy , 2019, Theranostics.

[18]  R. Schmid,et al.  New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness , 2019, Front. Oncol..

[19]  M. Stadler,et al.  The nuclear export inhibitor aminoratjadone is a potent effector in extracellular-targeted drug conjugates† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c8sc05542d , 2019, Chemical science.

[20]  Yijun Wang,et al.  Targeting the untargetable KRAS in cancer therapy , 2019, Acta pharmaceutica Sinica. B.

[21]  Pilhan Kim,et al.  Neutrophils disturb pulmonary microcirculation in sepsis-induced acute lung injury , 2019, European Respiratory Journal.

[22]  Robert Langer,et al.  Inhaled Nanoformulated mRNA Polyplexes for Protein Production in Lung Epithelium , 2019, Advanced materials.

[23]  Zheng Han,et al.  Synthesis and Evaluation of pH-Sensitive Multifunctional Lipids for Efficient Delivery of CRISPR/Cas9 in Gene Editing , 2018, Bioconjugate chemistry.

[24]  Angus P R Johnston,et al.  The Endosomal Escape of Nanoparticles: Toward More Efficient Cellular Delivery. , 2018, Bioconjugate chemistry.

[25]  P. Kantoff,et al.  Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA , 2018, Nature Biomedical Engineering.

[26]  Pilhan Kim,et al.  Intravital imaging of a pulmonary endothelial surface layer in a murine sepsis model. , 2018, Biomedical optics express.

[27]  Jia-You Fang,et al.  Inhalable particulate drug delivery systems for lung cancer therapy: Nanoparticles, microparticles, nanocomposites and nanoaggregates. , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[28]  P. Lyne,et al.  Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS , 2017, Science Translational Medicine.

[29]  Johannes Schindelin,et al.  TrackMate: An open and extensible platform for single-particle tracking. , 2017, Methods.

[30]  M. Amiji,et al.  Enhanced Anti-Tumor Efficacy of Lipid-Modified Platinum Derivatives in Combination with Survivin Silencing siRNA in Resistant Non-Small Cell Lung Cancer , 2016, Pharmaceutical Research.

[31]  Song Shen,et al.  Tumor Acidity-Sensitive Polymeric Vector for Active Targeted siRNA Delivery. , 2015, Journal of the American Chemical Society.

[32]  Somin Lee,et al.  Suppression of tumor growth in lung cancer xenograft model mice by poly(sorbitol-co-PEI)-mediated delivery of osteopontin siRNA. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[33]  Wei-qun Chen,et al.  GnRH participates in the self-renewal of A549-derived lung cancer stem-like cells through upregulation of the JNK signaling pathway. , 2015, Oncology reports.

[34]  Zheng-Rong Lu,et al.  Multifunctional cationic lipid-based nanoparticles facilitate endosomal escape and reduction-triggered cytosolic siRNA release. , 2014, Molecular pharmaceutics.

[35]  Y. Kopelman,et al.  Mutant KRAS is a druggable target for pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.

[36]  Clement Kleinstreuer,et al.  Nanoparticle mass transfer from lung airways to systemic regions--Part I: Whole-lung aerosol dynamics. , 2013, Journal of biomechanical engineering.

[37]  Zheng-Rong Lu,et al.  Design and evaluation of new pH-sensitive amphiphilic cationic lipids for siRNA delivery. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[38]  Robert Langer,et al.  Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug , 2013, Proceedings of the National Academy of Sciences.

[39]  C. Galbán,et al.  Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. , 2012, The Journal of clinical investigation.

[40]  S. Elledge,et al.  Functional identification of optimized RNAi triggers using a massively parallel sensor assay. , 2011, Molecular cell.

[41]  Zicai Liang,et al.  Elimination pathways of systemically delivered siRNA. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[42]  Gediminas Mainelis,et al.  Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance , 2010, Proceedings of the National Academy of Sciences.

[43]  P. Shapiro,et al.  Phospholipid-induced in vivo particle migration to enhance pulmonary deposition. , 2008, Journal of aerosol medicine and pulmonary drug delivery.

[44]  Zheng-Rong Lu,et al.  Novel polymerizable surfactants with pH-sensitive amphiphilicity and cell membrane disruption for efficient siRNA delivery. , 2007, Bioconjugate chemistry.

[45]  J. Kjems,et al.  The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. , 2007, Biomaterials.

[46]  Jean-Philippe Vert,et al.  An accurate and interpretable model for siRNA efficacy prediction , 2006, BMC Bioinformatics.

[47]  J. Patton.  Unlocking the opportunity of tight glycaemic control , 2005, Diabetes, obesity & metabolism.

[48]  S. Randell,et al.  Murine epithelial cells: isolation and culture. , 2004, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[49]  H. Varmus,et al.  Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. , 2001, Genes & development.

[50]  S. Belinsky,et al.  Refinement of an Orthotopic Lung Cancer Model in the Nude Rat , 2001, Veterinary pathology.

[51]  L. Chin,et al.  Essential role for oncogenic Ras in tumour maintenance , 1999, Nature.

[52]  A. Schally,et al.  Growth-Inhibitory Actions of Analogues of Luteinizing Hormone Releasing Hormone on Tumor Cells , 1997, Trends in Endocrinology & Metabolism.

[53]  K. Sikora,et al.  The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors. , 1990, British Journal of Cancer.

[54]  V. Torchilin,et al.  Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery. , 2013, Biomaterials.